Stage II-IV Ovarian Cancer

Adding Cediranib to Olaparib Markedly Improves Progression-Free Survival but Increases Toxicity in Recurrent Platinum-Sensitive Ovarian Cancer (10-21-2014)

The addition of the antiangiogenic agent cediranib to the PARP inhibitor olaparib in women with recurrent platinum-sensitive ovarian cancer improves time to cancer progression and survival. The results of this study were recently reported in The Lancet... Continue Reading

Aspirin as Ovarian Cancer Prevention? Research Says Maybe (02-20-2014)

New evidence suggests that an aspirin a day may reduce the risk of ovarian cancer. But more research is needed before your doctor will routinely prescribe it for prevention. You may know that low doses of aspirin, taken daily, can help reduce the risk... Continue Reading

Dacogen Helps Recurrent Ovarian Cancer Respond to Vaccine (01-30-2014)

Treatment with Dacogen® (decitabine) prior to the administration of Adriamycin® (doxorubicin) and a cancer vaccine yielded clinical benefit for women with recurrent ovarian cancer, according to a study published in Cancer Immunology Research. Ovarian... Continue Reading

Dose-Dense Paclitaxel Plus Carboplatin Improves Long-Term Survival in Advanced Ovarian Cancer (09-18-2013)

Dose-dense paclitaxel plus carboplatin was associated with significantly improved progression-free and overall survival compared with conventional paclitaxel/carboplatin as first-line treatment in patients with advanced ovarian cancer, according to the... Continue Reading

Maintenance Therapy with Votrient Provides Benefit in Advanced Ovarian Cancer (06-13-2013)

In a Phase III clinical trial, treatment with Votrient® (pazopanib) after initial chemotherapy improved outcomes among women with advanced ovarian cancer. These results were presented at the 2013 Annual Meeting of the American Society of Clinical Oncology... Continue Reading

Delaying Chemotherapy Increases Mortality in Ovarian Cancer (04-12-2013)

Women with advanced ovarian cancer have significantly worse survival when they wait more than 25 days after surgery to start chemotherapy, according to the results of a study presented at the 2013 Society of Gynecologic Oncology Annual Meeting on Women’s... Continue Reading

Ovarian Cancer Rates Declining in Breast Cancer Survivors (02-7-2013)

The rate of second primary ovarian cancers after first primary breast cancer appears to be on the decline, according to the results of a study published in the Journal of Clinical Oncology. Each year in the United States, roughly 22,000 women are diagnosed... Continue Reading

Diabetes Drug May Help Prevent or Treat Ovarian Cancer (12-3-2012)

Metformin, a widely prescribed insulin-lowering drug for diabetes, has been associated with survival in ovarian cancer and is worthy of further study, as it may be considered for the prevention or treatment of ovarian cancer, according to the results... Continue Reading

Treatment at High-Volume Hospitals Leads to Lower Mortality Rates for Ovarian Patients (11-20-2012)

Ovarian cancer patients who undergo surgery at high-volume hospitals have better outcomes than those who are treated at low-volume hospitals, according to the results of a study published in the Journal of Clinical Oncology. This is the result not of... Continue Reading

Gene Helps Predict Response to Chemotherapy in Ovarian Cancer (09-28-2012)

Measuring the activity of a gene called FGF1 could help predict which women with ovarian cancer will benefit from platinum-based chemotherapy, according to the results of a study published in the British Journal of Cancer. Each year in the United States,... Continue Reading

« Previous PageNext Page »